Your Article Summary
New Data Describe Safety of Subcutaneous Administration of ORENCIA For Patients with Moderate to Severe Rheumatoid Arthritis
Bristol Myers-Squibb Company, 10/21/09
Bristol–Myers Squibb Company announced that new clinical data support continued development of a subcutaneous administration of ORENCIA for patients with moderate to severe rheumatoid arthritis.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 10/30/09
Gyrus PlasmaKinetic bipolar coagulation device for liver resection
Australian and New Zealand Journal of Surgery, 11/13/09
Article Search
Sponsor


See Latest Articles


